Cited by 717SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesCOVID-19 epidemiological studies

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

Open access

Hacisuleyman, Ezgi, Hale, Caryn, Saito, Yuhki, Blachere, Nathalie E., Bergh, Marissa, Conlon, Erin G., Schaefer-Babajew, Dennis J., DaSilva, Justin, Muecksch, Frauke, Gaebler, Christian, Lifton, Richard, Nussenzweig, Michel C., Hatziioannou, Theodora, Bieniasz, Paul D., Darnell, Robert B.·2021·New England Journal of Medicine

DOI 10.1056/nejmoa2105000PMC PMC8117968

Open this paper in CoChat — free account

Abstract

Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of clinical concern. In a cohort of 417 persons who had received the second dose of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine at least 2 weeks previously, we identified 2 women with vaccine breakthrough infection. Despite evidence of vaccine efficacy in both women, symptoms of coronavirus disease 2019 developed, and they tested positive for SARS-CoV-2 by polymerase-chain-reaction testing. Viral sequencing revealed variants of likely clinical importance, including E484K in 1 woman and three mutations (T95I, del142-144, and D614G) in both. These observations indicate a potential risk of illness after successful vaccination and subsequent infection with variant virus, and they provide support for continued efforts to prevent and diagnose infection and to characterize variants in vaccinated persons. (Funded by the National Institutes of Health and others.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2105000

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
Rambaut, A., Holmes, E. C., O’Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0770-5 · Cited by 2,543
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Self-citation
Evolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
Self-citation
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343
Self-citation
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308
Self-citation
SARS-CoV-2 evolution during treatment of chronic infection
Kemp, S. A., Collier, D. A., Datir, R. P., Ferreira, I. A. T. M., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C., Mlcochova, P., Lumb, I. U., et al. (2021) · Nature · doi:10.1038/s41586-021-03291-y · Cited by 1,097
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M. M., Bishop, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01318-5 · Cited by 697
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric virusesPreprint
Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · bioRxiv · doi:10.1101/2020.06.08.140871 · Cited by 600
Self-citation
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H.-H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201181 · Cited by 572
Self-citation
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
Stamatatos, L., Czartoski, J., Wan, Y.-H., Homad, L. J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E., Jennewein, M. F., MacCamy, A. J., et al. (2021) · Science · doi:10.1126/science.abg9175 · Cited by 557

Show all 11 references

Sorted by citations

Items 401–500 of 717

Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials
Lim, H. Y., Arip, M., Yahaya, A. A. A.-F. B., Jazayeri, S. D., Poppema, S., & Poh, C. L. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/5024 · Cited by 6
SARS-CoV-2 transmissibility compared between variants of concern and vaccination status
Wang, L., Didelot, X., Bi, Y., & Gao, G. F. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab594 · Cited by 8
Development and Evaluation of AccuPower COVID-19 Multiplex Real-Time RT-PCR Kit and AccuPower SARS-CoV-2 Multiplex Real-Time RT-PCR Kit for SARS-CoV-2 Detection in Sputum, NPS/OPS, Saliva and Pooled Samples
Suh, I. B., Lim, J., Kim, H. S., Rhim, G., Kim, H., Kim, H., Lee, S.-M., Park, H.-S., Song, H. J., Hong, M., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263341 · Cited by 6
Targeting of neutrophil activation in the early phase of the disease for prevention of Coronavirus disease‐19 severity
Sendo, F., Yoshitake, H., & Araki, Y. (2022) · Microbiology and Immunology · doi:10.1111/1348-0421.12978 · Cited by 5
COVID-19 vaccine uptake in United States counties: geospatial vaccination patterns and trajectories towards herd immunityPreprint
Chernyavskiy, P., Richardson, J. W., & Ratcliffe, S. J. (2021) · medRxiv · doi:10.1101/2021.05.28.21257946 · Cited by 6
COVID -19: EFFICACY AND SAFETY PROFILE OF MAIN VACCINES APPROVED FOR EMERGENCY USE AUTHORIZATION IN 2021
Allzain, H. (2021) · International Journal of Research -GRANTHAALAYAH · doi:10.29121/granthaalayah.v9.i7.2021.4062 · Cited by 5
Hesitancy towards COVID-19 booster vaccine among healthcare workers in Bangladesh
Shoshi, H. R., Basher, A. K., Pyash, A. S., Hossain, M. K., Chowdhury, F., & Hassan, M. Z. (2025) · BMC Health Services Research · doi:10.1186/s12913-025-12482-6 · Cited by 6
Coinfection with SARS-CoV-2 among patients with Streptococcus pneumoniae in Casablanca
Katfy, M., Kettani, A. E., Katfy, K., Diawara, I., Nzoyikorera, N., Boussetta, S., Abdallaoui, M. S., & Bousfiha, A. A. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10953-z · Cited by 5
COVID-19 Challenge: A Quest for Effective Vaccine Strategies Against Circulating and Emerging SARS-CoV-2 Variants
Yogesh, R., Srivastava, N., & Bukhari, S. N. A. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220701160116 · Cited by 5
Vaccine breakthrough infections with SARS-CoV-2: Why older adults need booster vaccinations
Ventura, M. I., Azizian, A., Evans, S. E., Velasquez, S., Arguello, J. C., & Warburton, K. D. (2022) · Public Health in Practice · doi:10.1016/j.puhip.2022.100307 · Cited by 5
Biological risk in Italian prisons: data analysis from the second to the fourth wave of COVID-19 pandemic
Franchi, C., Rossi, R., Malizia, A., Gaudio, P. D., & Giovanni, D. D. (2023) · Occupational and Environmental Medicine · doi:10.1136/oemed-2022-108599 · Cited by 5
Comparison of self-reported symptoms in COVID-19 patients who had or had not previously received COVID-19 mRNA vaccination
Hara, M., Furue, T., Fukuoka, M., Iwanaga, K., Matsuishi, E., Miike, T., Sakamoto, Y., Mukai, N., Kinugasa, Y., Shigyo, M., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2226575 · Cited by 5
Dynamic lymphocyte-CRP ratio as a predictor: a single-centre retrospective study on disease severity and progression in adult COVID-19 patients
Wang, D., Gao, Y., Lai, Q.-Q., Wu, D., Liu, H., Meng, H., Wang, X.-T., Tang, Y.-J., Xu, J., Zhang, J., et al. (2024) · Journal of International Medical Research · doi:10.1177/03000605241236278 · Cited by 5
Intranasal SARS-CoV-2 Vaccines: Indispensable and Inevitable
Adashi, E. Y., & Gruppuso, P. A. (2022) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2022.06.009 · Cited by 5
SARS-CoV-2 vaccine breakthrough infections (VBI) by Omicron variant (B.1.1.529) and consequences in structural and functional impact.
Abduljaleel, Z., Melebari, S., Athar, M., Dehlawi, S., Kumar, S., Aziz, S. A. A., Dannoun, A., Malik, S. M., Thasleem, J., & Doss, C. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110798 · Cited by 5
What we know and don’t know on SARS-CoV-2 and COVID-19
Silva-Ayarza, I., & Bachelet, V. C. (2021) · Medwave · doi:10.5867/medwave.2021.04.8198 · Cited by 7
Severe Acute Respiratory Syndrome- Coronavirus 2
Sjögren, M. H. (2021) · Anales de la Facultad de Medicina · doi:10.15381/anales.v82i1.20743 · Cited by 5
Ginseng Protects ACE2-Transgenic Mice from SARS-CoV-2 Infection
Seo, S. H. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2706180 · Cited by 5
A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamstersPreprint
Wuertz, K. M., Barkei, E. K., Chen, W.-H., Martinez, E. J., Lakhal-Naouar, I., Jagodzinski, L. L., Paquin‐Proulx, D., Gromowski, G. D., Swafford, I., Ganesh, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.16.448525 · Cited by 5
Memory B cells control SARS-CoV-2 variants upon mRNA vaccination of naive and COVID-19 recovered individualsPreprint
Sokal, A., Spaeth, G. B., Fernández, I., Broketa, M., Azzaoui, I., Selle, A. D. L., Vandenberghe, A., Fourati, S., Roeser, A., Meola, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.17.448459 · Cited by 5
COVID-19 convalescent plasma donors: impact of vaccination on antibody levels, breakthrough infections and reinfection ratePreprint
Raja, M. L., Pacenti, M., Ileana, G., Boldrin, C., Cattai, M., Erica, S., Anna, B., Michele, S., Alberto, R., Rosa, L. A., et al. (2021) · medRxiv · doi:10.1101/2021.07.13.21260414 · Cited by 5
Autoantibodies linked to autoimmune diseases associate with COVID-19 outcomesPreprint
Baiocchi, G. C., Vojdani, A., Rosenberg, A. Z., Vojdani, E., Halpert, G., Ostrinski, Y., Zyskind, I., Filgueiras, I. S., Schimke, L. F., Marques, A. H. C., et al. (2022) · medRxiv · doi:10.1101/2022.02.17.22271057 · Cited by 5
The Role of Laboratory-Based Viral Testing in the COVID-19 Pandemic
Pecora, N., & Pettengill, M. A. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvab227 · Cited by 4
Multicomponent vaccines to fight SARS-CoV-2 variants of concern
Cassone, A., & Cauda, R. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.069 · Cited by 4
Would New SARS-CoV-2 Variants Change the War against COVID-19?
Redwan, E. M. M. M., Elrashdy, F., Aljabali, A. A. A., Baetas‐da‐Cruz, W., Barh, D., Brufsky, A., Hassan, S. S., Lundstrom, K. H., Serrano‐Aroca, Á., Takayama, K., et al. (2022) · Epidemiologia · doi:10.3390/epidemiologia3020018 · Cited by 4
A Diagnostic Strategy for Gauging Individual Humoral Ex Vivo Immune Responsiveness Following COVID-19 Vaccination
Kuechler, A. S., Weinhold, S., Boege, F., Adams, O., Müller, L., Babor, F., Bennstein, S. B., Pham, T.-X. U., Hejazi, M., Reusing, S. B., et al. (2022) · Vaccines · doi:10.3390/vaccines10071044 · Cited by 4
Host tRNA-Derived RNAs Target the 3′Untranslated Region of SARS-CoV-2
Hendrickson, E. N., Ericson, M. E., & Bemis, L. (2022) · Pathogens · doi:10.3390/pathogens11121479 · Cited by 4
Identification of a Pentasaccharide Lead Compound with High Affinity to the SARS-CoV-2 Spike Protein via In Silico Screening
Li, B., Zhang, T., Cao, H., Ferro, V., Li, J., & Yu, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216115 · Cited by 4
Heterologous and homologous COVID-19 mRNA vaccination schemes for induction of basic immunity show similar immunogenicity regarding long-term spike-specific cellular immunity in healthcare workers
Wagenhäuser, I., Almanzar, G., Förg, F. B., Stein, A., Eiter, I., Reusch, J., Mees, J., Herzog, A. L., Vogel, U. F., Frey, A., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.07.033 · Cited by 7
Incidence and risk factors of SARS-CoV-2 breakthrough infection in the early Omicron variant era among vaccinated and boosted individuals in Chicago
Echevarria, F. M. M., Caputo, M., Camp, D. M., Reddy, S., & Achenbach, C. J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302338 · Cited by 4
Breakthrough herpes zoster following recombinant zoster vaccinations in a rheumatoid arthritis patient receiving a Janus kinase inhibitor: A case report and literature review
Nagata, S., & Yokogawa, N. (2025) · Modern Rheumatology Case Reports · doi:10.1093/mrcr/rxaf012 · Cited by 4
COVID-19 in fully vaccinated Everest trekkers in Nepal
Amatya, B., Pandey, P., Dawadi, S., & Manandhar, S. (2021) · Journal of Travel Medicine · doi:10.1093/jtm/taab098 · Cited by 4
Modeling-Based Estimate of the Vaccination Rate, Lockdown Rules and COVID-19
Guo, C., & Chang, W. (2021) · Healthcare · doi:10.3390/healthcare9101245 · Cited by 4
Immunological Biomarkers in Blood to Monitor the Course and Therapeutic Outcomes of COVID-19
Wieland, E. (2021) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000945 · Cited by 4
A Retrospective Cross-Sectional Study of Severe Breakthrough SARS-CoV-2 Infection in the General Population Requiring Hospitalization Within a Single Health System
Acharya, R., Kafle, S., KANDINATA, N. N., Slipman, B., Ghimire, M., & Trotter, A. B. (2022) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4662 · Cited by 4
Leishmaniac Quest for Developing a Novel Vaccine Platform. Is a Roadmap for Its Advances Provided by the Mad Dash to Produce Vaccines for COVID-19?
Chang, K. P., Reynolds, J. M., Liu, Y., & He, J. J. (2022) · Vaccines · doi:10.3390/vaccines10020248 · Cited by 4
The long-term effectiveness of coronavirus disease 2019 (COVID-19) vaccines: A systematic literature review and meta-analysis
Marra, A. R., Kobayashi, T., Suzuki, H., Alsuhaibani, M., Schweizer, M. L., Diekema, D. J., Tofaneto, B. M., Bariani, L. M., Auler, M. D. A., Salinas, J. L., et al. (2022) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2021.261 · Cited by 5
An adaptive, asymptomatic SARS-CoV-2 workforce screening program providing real-time, actionable monitoring of the COVID-19 pandemic
Hijano, D. R., Hoffman, J. M., Tang, L., Schultz‐Cherry, S., Thomas, P. G., Hakim, H., Webby, R. J., Hayden, R. T., Gaur, A. H., & St. Jude COVID-19 Employee Screening Program Team (2022) · PLoS ONE · doi:10.1371/journal.pone.0268237 · Cited by 4
Immunopathogenesis in SARS-CoV-2 and Mycobacterium tuberculosis: The danger of overlapping crises
Satapathy, P., Ratho, R. K., & Sethi, S. K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1065124 · Cited by 4
Expanding repertoire of SARS-CoV-2 deletion mutations contributes to evolution of highly transmissible variants
Venkatakrishnan, A., Anand, P., Lenehan, P. J., Ghosh, P., Suratekar, R., Silvert, E., Pawlowski, C., Siroha, A., Chowdhury, D. R., O’Horo, J. C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-022-26646-5 · Cited by 5
The Impact of Vaccination Among Hospitalized Patients with the Diagnosis of COVID-19
Yıldız, Y., Özger, H. S., Acar, A., Keski̇n, A. S., Binay, U. D., Ünlü, G., Bayram, H., Aslan, A., Akça, M. Ö., Karamanlıoğlu, D., et al. (2023) · Infectious Diseases and Clinical Microbiology · doi:10.36519/idcm.2023.216 · Cited by 4
Employment of a high throughput functional assay to define the critical factors that influence vaccine induced cross-variant neutralizing antibodies for SARS-CoV-2
Gu, Y., Shunmuganathan, B. D. O., Qian, X., Gupta, R., Tan, R. S. W., Kozma, M., Purushotorman, K., Murali, T. M., Tan, N. Y., Preiser, P. R., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-49231-w · Cited by 8
Unravelling humoral immunity in SARS-CoV-2: Insights from infection and vaccination
Najimi, N., Kadi, C., Elmtili, N., Seghrouchni, F., & Bakri, Y. (2024) · Human Antibodies · doi:10.3233/hab-230017 · Cited by 4
Recomendaciones SEPAR y nuevos retos sobre la vacuna contra la COVID-19 en las enfermedades respiratorias
de la Rosa, D., López-Campos, J. L., Blanco‐Aparicio, M., & Álvarez, F. V. (2021) · Vacunas · doi:10.1016/j.vacun.2021.05.001 · Cited by 4
A single dose of the Biontech/Pfizer BNT162b2 vaccine protected elderly residents from severe COVID‐19 during a SARS‐coronavirus‐2 outbreak in a senior citizen home in Germany
Schwarzer, R., Freys, S. D., Neuwinger, N., Beikert, N., Eberspächer, B., Edelmann, A., Żuchowski, M., Slothouwer, I., Stein, A., Theil, K., et al. (2021) · Immunity Inflammation and Disease · doi:10.1002/iid3.532 · Cited by 4
SARS COV-2 anti-nucleocapsid and anti-spike antibodies in an emergency department healthcare worker cohort: September 2020 – April 2021
Wang, R. C., Murphy, C. E., Kornblith, A. E., Hohenstein, N. A., Carter, C. M., Wong, A. H. K., Kurtz, T. W., & Kohn, M. A. (2022) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2022.01.055 · Cited by 4
How to Deal With Vaccine Breakthrough Infection With SARS-CoV-2 Variants
Guo, Y., Jun, M., Liu, C., Chen, G., Chi, Y., Zheng, S., & Wang, H. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.842303 · Cited by 4
The Epidemiological, Clinical Features and Outcomes of Imported Chinese COVID-19 Patients Following Inactivated Vaccines Injection
Li, J., Jiang, N., Zeng, Q., Zhang, Y., He, X., Chu, Y., Jin, W., Liu, Y., Shi, W., Yang, M. S., et al. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s356460 · Cited by 4
SARS-CoV-2 Variants in Rhode Island; May 2022 Update.
Singh, M., Novitsky, V., Carpenter‐Azevedo, K., Howison, M., Huard, R. C., King, E., & Kantor, R. (2022) · PubMed · Cited by 4
Epidemiological characteristics and quarantine assessment of imported international COVID-19 cases, March to December 2020, Chengdu, China
Zhang, W., Yue, Y., Min, H., Du, C., Wang, C., Tuo, X., Jiang, X., Fan, S., Chen, Z., Chen, H., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-20712-8 · Cited by 4
Lessons drawn from Shanghai for controlling highly transmissible SARS-CoV-2 variants: insights from a modelling study
Wang, H., Li, T., Gao, H. B., Huang, C., Tang, B., Tang, S., Cheke, R., & Zhou, W. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08316-7 · Cited by 4
Immunogenicity and safety of the homogenous booster shot of a recombinant fusion protein vaccine (V-01) against COVID-19 in healthy adult participants primed with a two-dose regimenPreprint
Li, Y., Fang, X. D., Pei, R., Fan, R., Chen, S., Zeng, P., Ou, Z., Deng, J., Zhou, J., Sun, Z., et al. (2021) · medRxiv · doi:10.1101/2021.11.04.21265780 · Cited by 3
Defining Factors that Influence vaccine-induced, cross-variant neutralizing antibodies for SARS-CoV-2 in AsiansPreprint
Gu, Y., Shunmuganathan, B. D. O., Qian, X., Gupta, R., Tan, R. S. W., Kozma, M., Purushotorman, K., Murali, T. M., Tan, N. Y. J., Preiser, P. R., et al. (2022) · medRxiv · doi:10.1101/2022.03.06.22271809 · Cited by 4
Clinical, immunological and genomic analysis of the post vaccinated SARS-CoV-2 infected cases with Delta derivatives from Maharashtra, India, 2021
Yadav, P. D., Sahay, R. R., Agrawal, S. R., Shete, A. M., Adsul, B. B., Tripathy, S. P., Nyayanit, D. A., Manrai, M., Patil, D. Y., Kumar, S., et al. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.04.014 · Cited by 4
Molnupiravir for treating COVID-19
Tatz, G., Ochodo, E., Fox, T., Owino, E. J., Nyagol, B., Rupali, P., McCaul, M., Kredo, T., & Cohen, K. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015381.pub2 · Cited by 3
Surfing Corona waves – instead of breaking them: Rethinking the role of natural immunity in COVID-19 policy
Kalk, A., Sturmberg, J. P., Damme, W. V., Brown, G. W., Ridde, V., Zizi, M., & Paul, É. (2022) · F1000Research · doi:10.12688/f1000research.110593.1 · Cited by 3
Predicting the negative conversion time of nonsevere COVID‐19 patients using machine learning methods
Ye, J., Shao, X., Yang, Y., & Zhu, F. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28747 · Cited by 3
Factors Associated with SARS-CoV-2 Infection before Vaccination among European Health Care Workers
Mansour, I., Godono, A., Sansone, E., Visci, G., Spiteri, G., Monaco, M. G. L., Mateș, D., Rașcu, A., Duval, X., Pira, E., et al. (2023) · La Medicina del Lavoro · doi:10.23749/mdl.v114i3.14422 · Cited by 3
SARS-CoV-2 Nsp13 helicase modulates miR-146a-mediated signaling pathways
Lundrigan, E., Uguccioni, S. M., Hum, C., Ahmed, N., & Pezacki, J. P. (2025) · Virology · doi:10.1016/j.virol.2025.110493 · Cited by 3
Characterizing spatial epidemiology in a heterogeneous transmission landscape using the spatial transmission count statistic
Lyu, L., Veytsel, G. E., Stott, G., Fox, S. J., Dailey, C., Damodaran, L., Fujimoto, K., Brown, P., Sealy, R., Brown, A. O., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00888-6 · Cited by 3
Duration of immunity following infection with moderately virulent ASFV
Friedrichs, V., Deutschmann, P., Wernike, K., Carrau, T., Beer, M., Blome, S., & Schäfer, A. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1014018 · Cited by 3
Symptomatic SARS-CoV-2 Infection with Ageusia after Two mRNA Vaccine Doses
Caponio, V. C. A., Lipsi, M. R., Fortunato, F., Arena, F., & Muzio, L. L. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19020886 · Cited by 3
Endoscopy After the COVID-19 Pandemic—What Will Be Different?
Lui, R. N.-S., Tang, R. S. Y., & Chiu, P. W. Y. (2022) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-022-00370-5 · Cited by 3
Development of a new antigen-based microarray platform for screening and detection of human IgG antibodies against SARS-CoV-2
Burgold-Voigt, S., Müller, E., Zopf, D., Monecke, S., Braun, S. D., Frankenfeld, K., Kiehntopf, M., Weis, S., Schumacher, T., Pletz, M. W., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-10823-7 · Cited by 3
COVID-19 Vaccination Status Among Healthcare Workers and Its Effect on Disease Manifestations: A Study From Northeast India
Jamil, M., Bhattacharya, P. K., Barman, B., Lynrah, K. G., Lyngdoh, M., Tiewsoh, I., Gupta, A. K., Mandal, A., Sahoo, D. P., & Sathees, V. (2022) · Cureus · doi:10.7759/cureus.25159 · Cited by 3
Guidance for Cardiopulmonary Resuscitation of Children With Suspected or Confirmed COVID-19
Morgan, R. W., Atkins, D. L., Hsu, A., Kamath‐Rayne, B. D., Aziz, K., Berg, R. A., Bhanji, F., Chan, M., Cheng, A., Chiotos, K., et al. (2022) · PEDIATRICS · doi:10.1542/peds.2021-056043 · Cited by 3
Emergence of COVID-19 Variants and Its Global Impact
Kunal, S., Ish, P., Aditi, & Gupta, K. (2022) · Springer eBooks · doi:10.1007/978-3-031-08045-6_9 · Cited by 3
Rapid and convenient detection of SARS-CoV-2 using a colorimetric triple-target reverse transcription loop-mediated isothermal amplification method
Yang, Z., Liu, N., Zhu, Z., Xiao, M., Zhong, S., Xue, Q., Nie, L., & Zhao, J. (2022) · PeerJ · doi:10.7717/peerj.14121 · Cited by 3
Immune Persistence against SARS-CoV-2 after Primary and Booster Immunization in Humans: A Large-Scale Prospective Cohort Study
Li, J., Xie, H., Chen, W., Chen, M., Bai, S., Zhao, W., Zhou, T., Gao, P., Zhang, L., Wang, Q., et al. (2022) · Vaccines · doi:10.3390/vaccines10101677 · Cited by 3
Use of a Preclinical Natural Transmission Model to Study Antiviral Effects of a Carbohydrate-Binding Module Therapy against SARS-CoV-2 in Hamsters
Knott, D., Fell, R., Potter, J. A., Yuille, S., Salguero, F. J., Graham, V., Hewson, R., Howat, D., & Dowall, S. (2023) · Viruses · doi:10.3390/v15030725 · Cited by 3
Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study
Puspitasari, M., Sattwika, P. D., Hidayat, A. R. P., Wijaya, W., Wardhani, Y., Intansari, U. S., Kertia, N., Purwanto, B., & Thobari, J. A. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03218-x · Cited by 3
Prevalence, Clinical Profile and Determinants of COVID-19 Vaccination and SARS-CoV-2 Breakthrough Infection in Douala, Cameroon
Soubgui, A. F. M., Foko, L. P. K., Enyegue, E. L. E., Mboussi, W. S. N., & Mogtomo, M. L. K. (2023) · Trends in Medical Research · doi:10.3923/tmr.2023.122.135 · Cited by 3
Vaccination Shapes Within-Host SARS-CoV-2 Diversity of Omicron BA.2.2 Breakthrough Infection
Zhang, Y., Zhou, Y., Chen, J., Wu, J., Wang, X., Zhang, Y., Wang, S., Cui, P., Xu, Y., Li, Y., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad572 · Cited by 3
Elucidating the Immune Response to SARS-CoV-2: Natural Infection versus Covaxin/Covishield Vaccination in a South Indian Population
Vanamudhu, A., Arumugam, R. D., Nancy, A., Selvaraj, N., Moideen, K., Hissar, S. S., Ranganathan, U. D., Bethunaickan, R., Babu, S., & Kumar, N. P. (2024) · Viruses · doi:10.3390/v16081178 · Cited by 3
Case Report: Severe COVID-19 in a Kidney Transplant Recipient Without Humoral Response to SARS-CoV-2 mRNA Vaccine Series
Yamada, M., Matsumoto, E., Thomas, C. P., Carlson, J. R., Klutts, J. S., Kumar, B., Streit, J. A., & Swee, M. L. (2021) · Transplantation Direct · doi:10.1097/txd.0000000000001193 · Cited by 3
Roll-out of vaccination against COVID-19 pandemic
Liang, X., He, G., Ma, W., & Xiao, J. (2021) · Infectious Diseases of Poverty · doi:10.1186/s40249-021-00902-8 · Cited by 3
Review of studies on SARS-CoV-2 infection inhibitors
Michalski, A., Wójcicka, P., Bielawska-Drózd, A., & Bartoszcze, M. (2021) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/143035 · Cited by 3
SARS-CoV-2 immunity and an overview of the COVID-19 vaccines
Marković, M. (2021) · Medicinski podmladak · doi:10.5937/mp72-33315 · Cited by 3
A Call for Caution in the Immunocompromised: Coronavirus Disease 2019 Associated With Mortality in a Vaccinated Lung Transplant Recipient
Hogan, J. I., & Kotton, C. N. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab557 · Cited by 3
Update to COVID-19 serologic testing : FAQs and caveats
Kadkhoda, K. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.87a.20054-up · Cited by 3
Determinants of the willingness to get the third COVID-19 vaccine dose among health care workers
Paris, C., Saade, A., Tadié, É., Van, R. N., Turmel, V., Garlantézec, R., & Tattevin, P. (2022) · Infectious Diseases Now · doi:10.1016/j.idnow.2022.04.007 · Cited by 3
Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines
Zhu, Y., Lü, Y., Zhou, C., Tong, G., Gao, M., Zhan, Y., Wang, Y., Liang, R., Li, Y., Gao, T., et al. (2022) · Med · doi:10.1016/j.medj.2022.05.003 · Cited by 3
Sequence similarity of SARS-CoV-2 and humans: Implications for SARS-CoV-2 detection
Li, H., Hong, X., Ding, L., Meng, S., Liao, R., Jiang, Z., & Liu, D. J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.946359 · Cited by 5
Genomic monitoring unveils a high prevalence of severe acute respiratory syndrome coronavirus 2 Omicron variant in vaccine breakthrough cases in Bahia, Brazil
Campos, G. S., Giovanetti, M., de Moraes, L. E. P., da Hora, H. S., Bandeira, A. C., Alcantara, K. V. O. M. D., & Sardi, S. I. (2023) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20220955 · Cited by 4
COVID-19 outbreak in a long-term care facility in Kelowna, British Columbia after rollout of COVID-19 vaccine in March 2021
Sabet, F., Gauthier, B., Siddiqui, M., Wilmer, A., Prystajecky, N., Rydings, P., Andrews, M., & Pollock, S. (2021) · Canada Communicable Disease Report · doi:10.14745/ccdr.v47i12a05 · Cited by 2
Broadly neutralizing antibodies against SARS-CoV-2 variants
Zhang, L. (2022) · National Science Open · doi:10.1360/nso/20220005 · Cited by 3
Highly valued despite burdens: Qualitative implementation research on rapid tests for hospital-based SARS-CoV-2 screening
Wachinger, J., McMahon, S. A., Lohmann, J., Allegri, M. D., & Denkinger, C. M. (2022) · SSM - Qualitative Research in Health · doi:10.1016/j.ssmqr.2022.100140 · Cited by 3
Antibody levels over time against the novel coronavirus and incidence of adverse reaction after vaccination
Kasuga, I., Gamo, S., Yokoe, Y., SUGIYAMA, T., TOKURA, M., NOGUCHI, M., Okayama, M., TAKEDA, Y., SATO, T. A., Mori, M., et al. (2022) · Health Evaluation and Promotion · doi:10.7143/jhep.49.462 · Cited by 3
Real-Time Analysis of SARS-CoV-2-Induced Cytolysis Reveals Distinct Variant-Specific Replication Profiles
Scheuermann, S. E., Goff, K. A., Rowe, L. A., Beddingfield, B. J., & Maness, N. J. (2023) · Viruses · doi:10.3390/v15091937 · Cited by 3
Post vaccination COVID-19 infection among health care workers in secondary medical care centre
Pandurangaiah, R., Leela, G. R., Jose, D. T., & Mathew, D. R. (2021) · International Journal of Clinical Obstetrics and Gynaecology · doi:10.33545/gynae.2021.v5.i3c.920 · Cited by 3
Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines
Pelletier, A. N., Sékaly, R., & Tomalka, J. A. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.11.012 · Cited by 3
A simple stochastic theory of extinction shows rapid elimination of a Sars-like pandemicPreprint
Khatri, B. S. (2020) · medRxiv · doi:10.1101/2020.08.10.20171454 · Cited by 3
COVID-19 Vaccine Intentions in the United States—December 2020 to March 2021Preprint
Czeisler, M. É., Rajaratnam, S. M. W., Howard, M. E., & Czeisler, C. A. (2021) · medRxiv · doi:10.1101/2021.05.16.21257290 · Cited by 3
Breakthrough COVID-19 infections among health care workers after two doses of ChAdOx1 nCoV-19 vaccine
Kumar, R., Kodan, P., Aggarwal, R., Deepak, G. P., & Trikha, A. (2021) · QJM · doi:10.1093/qjmed/hcab205 · Cited by 3
Spread of SARS-CoV-2 Delta variant infections bearing the S:E484Q and S:T95I mutations in July and August 2021 in FrancePreprint
Verdurme, L., Danesh, G., Trombert‐Paolantoni, S., Sofonea, M. T., Noel, V., Foulongne, V., Montès, B., Tuaillon, É., Haïm‐Boukobza, S., Roquebert, B., et al. (2021) · medRxiv · doi:10.1101/2021.09.13.21263371 · Cited by 3
Predicting COVID-19 Vaccine Efficacy from Neutralizing Antibody LevelsPreprint
Abedi, M. R., Dixon, S. L., Guyon, T., Hsu, S., Jacobs, A. R., Nair, L. J., & Terbrueggen, R. H. (2021) · medRxiv · doi:10.1101/2021.10.13.21264921 · Cited by 3
Waning immune responses against SARS-CoV-2 among vaccinees in Hong KongPreprint
Peng, Q., Zhou, R., Wang, Y., Zhao, M., Liu, N., Li, S., Huang, H., Yang, D., Au, K., Wang, H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.22.473934 · Cited by 3
High Frequencies of PD-1 + TIM3 + TIGIT + CTLA4 + Functionally Exhausted SARS-CoV-2-Specific CD4 + and CD8 + T Cells Associated with Severe Disease in Critically ill COVID-19 PatientsPreprint
Coulon, P.-G. A., Prakash, S., Dhanushkodi, N. R., Srivastava, R., Zayou, L., Tifrea, D. F., Edwards, R. A., Cesar, J. F., Schubl, S. D., Hsieh, L. L., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.30.478343 · Cited by 4
Characterization of various remdesivir-resistant mutations of SARS-CoV-2 by mathematical modeling and molecular dynamics simulationPreprint
Torii, S., Kim, K. S., Koseki, J., Suzuki, R., Iwanami, S., Fujita, Y., Jeong, Y. D., Matsuura, Y., Shimamura, T., Iwami, S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.22.481436 · Cited by 3
Genomic Surveillance of SARS CoV2 in COVID-19 vaccinated healthcare workers in LebanonPreprint
Alkalamouni, H., Hassan, F. F. A., Hamdan, M. B., Page, A. J., Lott, M. C., Ghosn, N., Rady, A., Mahfouz, R. A., Araj, G. F., Dbaibo, G. S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.06.494965 · Cited by 3

Authors: Hacisuleyman, E., Hale, C., Saito, Y., Blachere, N. E., Bergh, M., Conlon, E. G., Schaefer-Babajew, D. J., DaSilva, J., Muecksch, F., Gaebler, C., Lifton, R., Nussenzweig, M. C., Hatziioannou, T., Bieniasz, P. D., & Darnell, R. B.
Affiliations: Howard Hughes Medical Institute (US)
From the Laboratory of Molecular Neuro-oncology (E.H., C.H., Y.S., N.E.B., M.B., E.G.C., R.B.D.), the Laboratory of Molecular Immunology (D.J.S.-B., C.G., M.C.N.), the Laboratory of Human Genetics and Genomics (R.L.), the Laboratory of Retrovirology (J.D., F.M., T.H., P.D.B.), and the Howard Hughes Medical Institute (M.C.N., P.D.B., R.B.D.), Rockefeller University, New York.
Corresponding author: Darnell, Robert B.
ORCID: Hacisuleyman, Ezgi
Hale, Caryn
Bergh, Marissa
Schaefer-Babajew, Dennis J.
DaSilva, Justin
Muecksch, Frauke
Gaebler, Christian
Lifton, Richard
Nussenzweig, Michel C.
Bieniasz, Paul D.
Darnell, Robert B.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2021-06-10
Volume: 384
Issue: 23
Pages: 2212-2218
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2105000
PMC: PMC8117968
OpenAlex: W3153636933
Cited by: 716
References: 11
Citations by year: 2026: 12 · 2025: 20 · 2024: 42 · 2023: 102 · 2022: 298 · 2021: 239
FWCI: 54.00
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Howard Hughes Medical Institute
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Keywords: SARS-CoV-2 variants, breakthrough infection, COVID-19 vaccination, BNT162b2, mRNA-1273, E484K mutation, D614G mutation, viral genome sequencing, vaccine efficacy
MeSH terms: COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, 2019-nCoV Vaccine mRNA-1273, Aged, Antibodies, Viral, Female, Humans, Middle Aged, Mutation, Neutralization Tests, Phylogeny, Polymerase Chain Reaction, Sequence Analysis, RNA, Viral Load, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks